Spexis AG

Equities

POLN

CH0106213793

Pharmaceuticals

Delayed Swiss Exchange 05:35:56 2024-03-28 am EDT 5-day change 1st Jan Change
0.08 CHF +6.67% Intraday chart for Spexis AG +3.90% +95.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ascom Hires New CFO MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis MT
Spexis Secures Debt-restructuring Moratorium From Swiss Court MT
Spexis Seeks Loan Restructuring to Support Cystic Fibrosis Drug Study MT
Spexis to File for Debt-restructuring Moratorium in Switzerland; Stock Sinks MT
Spexis CFO to Step Down, Interim CFO Named MT
Spexis AG Announces Executive Changes, Effective December 1, 2023 CI
Muriel Fleming Joins Spexis AG as Executive Committee, Effective December 1, 2023 CI
Transcript : Polyphor AG - Special Call
Spexis Posts Lower H1 Attributable Loss MT
Spexis AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Spexis AG Announces Appointment of Gonçalo Bernardes as Acting Head of Chemical Biology CI
Spexis Secures Investment Pledge from SPRIM Global, Other Investors for ColiFin Trial MT
Spexis AG announced that it has received $2.5 million in funding from SPRIM Ventures and other investors CI
Spexis Enlists Financial Adviser to Evaluate Strategic Alternatives, Fundraising Opportunities MT
Spexis AG Announces the Publication of Preclinical Results from its Novel Class of Macrocyclic, Peptidomimetic Antibiotics Developed in Collaboration with the University of Zurich CI
Spexis AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Spexis Posts Higher FY22 Attributable Net Loss; Operating Loss Widens MT
Destiny Pharma picks interim CEO as Clark makes quick exit AN
Spexis Receives Extension for Publication of 2022 Annual Report MT
Spexis AG announced that it has received $4.5 million in funding from SPRIM Ventures CI
Spexis and SPRIM Global Investments Announces Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin® CI
Spexis Strikes Clinical Trial Partnership to Develop Lung Infection Drug ColiFin MT
Spexis AG announced that it has received $0.5 million in funding from SPRIM Ventures CI
Chart Spexis AG
More charts
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Spexis AG - Swiss Exchange
  4. News Spexis AG
  5. Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change